

## **DEPARTMENT OF HEALTH & HUMAN SERVICES**

**Public Health Service** 

Food and Drug Administration Washington, DC 20204

## 3633 01 MAR 16 A7:17

MAR - 5 2001

Mr. Ira Goldberg President Source Naturals, Inc. Scotts Valley, California 95066

Dear Mr. Goldberg:

This is in response to your letter of December 5, 2000 to the Food and Drug Administration (FDA) pursuant to 21 U.S.C. 343(r)(6) (section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act (the Act)). Your submission states that Source Naturals, Inc., is making the following claim, among others, for the product **Cholestrex**:

"...may help to maintain healthy cholesterol levels when consumed as part of a low-cholesterol and low dietary program."

21 U.S.C. 343(r)(6) makes clear that a statement included in labeling under the authority of that section may not claim to diagnose, mitigate, treat, cure, or prevent a specific disease or class of diseases. The statement that you are making for this product suggests that it is intended to treat, prevent, or mitigate disease. This claim does not meet the requirements of 21 U.S.C. 343(r)(6). This claim suggests that this product is intended for use as a drug within the meaning of 21 U.S.C. 321(g)(1)(B), and that it is subject to regulation under the drug provisions of the Act. If you intend to make claims of this nature, you should contact FDA's Center for Drug Evaluation and Research (CDER), Office of Compliance, HFD-310, 7520 Standish Place, Rockville, Maryland 20855.

LET 461 975 0163

Page 2 - Mr. Ira Goldberg

Please contact us if you require further assistance.

Sincerely,

John B. Foret Director Division of Compliance and Enforcement Office of Nutritional Products, Labeling and Dietary Supplements Center for Food Safety and Applied Nutrition

Copies:

FDA, Center for Drug Evaluation and Research, Office of Compliance, HFD-300 FDA, Office of the Associate Commissioner for Regulatory Affairs, Office of Enforcement, HFC-200 FDA, San Francisco District Office, Office of Compliance, HFR-PA150 Page 3 - Mr. Ira Goldberg

cc: HFA-224 (w/incoming) HFA-305 (docket 97S-0163) HFS-22 (CCO) HFS-800 (r/f, file) HFS-811 (file) HFD-40 (Behrman) HFD-310 HFD-314 (Aronson) HFS-605 HFV-228 (Benz) GCF-1 (Nickerson) f/t:HFS-811:afp:02/08/01:docname:74382:disc1

Source Naturals. Inc. Scotts Valley, CA 95066

<u>1</u>

December 5, 2000

Office of Special Nutritionals (HFS-450) Center for Food Safety and Applied Nutrition Food and Drug Administration 200 C St. SW., Washington, D.C. 20204

RE: Notification of Nutritional Support Statements

Dear Sir or Madam:

I hereby notify the Food and Drug Administration (FDA) of the use of statements of nutritional support in the labeling of Cholestrex, a dietary supplement. Source Naturals<sup>®</sup> is the manufacturer of Cholestrex.

Statements being made in the labeling of Cholestrex:

(1) Preliminary scientific evidence suggests that certain fibers, niacin, beta-sitosterol and other nutrients may help to maintain healthy cholesterol levels when consumed as part of a low-cholestrial and low-fat dietary program.

To the best of my knowledge, and based upon information and belief present at the time of the execution of this notice, I certify that the above information is accurate and complete. Source Naturals possesses substantiation that the statements are truthful and not misleading.

Goldberg

President, Source Naturals, Inc.

1450-